Hyman B. Muss Addresses Misconceptions About Pregnancy and Breast Cancer

Video

Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses misconceptions women have about being pregnant with a breast cancer diagnosis.

Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses misconceptions women have about being pregnant with a breast cancer diagnosis.

While the cancer may initially be more difficult to find since pregnant women’s bodies are going through changes, the treatment and outcomes are about the same when compared to patients with breast cancer who are not pregnant. Muss emphasizes that being pregnant does not mean choosing between treating cancer and having a healthy baby.

Recent Videos
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
5 experts in this video
Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content
Line illustration of an IV drip in gold on a dark blue background

FDA Approves Denosumab Biosimiliars for Prior Authorized Indications

Tim Cortese
March 13th 2025
Article

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Line illustration of a breast with tissue on a cerulean background

Frontline Camizestrant Combo Increases PFS In Breast Cancer Subtypes

Kyle Doherty
March 5th 2025
Article

Camizestrant with a CDK4/6 inhibitor was well tolerated and effective as first-line therapy for patients with ESR1-mutated, HR-positive/HER2-negative advanced breast cancer.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Blue image of a breast with tissue and a tumor highlighted in orange

KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer

Ashling Wahner
February 17th 2025
Article

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

Simple line illustration of breast tissue on a yellow background

PFS, Tolerability Increase With Lerociclib/Fulvestrant in HR+/HER– Breast Cancer

Roman Fabbricatore
February 10th 2025
Article

Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.